Specify a stock or a cryptocurrency in the search bar to get a summary
Jiangsu Hengrui Medicine Co Ltd
600276Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, develops, manufactures, and commercializes drugs worldwide. The company is developing Camrelizumab, Pyrotinib, Fuzuloparib, Adebrelimab, Rezvilutamide, Famitinib, Dalpiciclib, SHR-1701, SHR-1501, SHR-A1811, SHR1459, Mecapegfilgrastim, Apatinib, Linperlisib, and SHR2554 for oncology indications; SHR4640, Retagliptin, SHR20004, SHR-1209, SHR3824, INS068, SHR7280, and SHR2285 for cardiovascular and metabolism indications. It is also developing SHR0302, Hetrombopag, Vunakizumab, and SHR-1703 for autoimmune indications; SHR0410, Imrecoxib, Remimazolam, and SHR8554 for pain; Oteseconazole and HRS9950 for anti-infection; and SHR8028, SHR8058, SHR-1707, and SHR-1222 for other indications. The company was founded in 1970 and is based in Lianyungang, China. Address: No. 38, Huanghe Road, Lianyungang, China, 222000
Analytics
WallStreet Target Price
403.57 CNYP/E ratio
55.6977Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 600276
Dividend Analytics 600276
Dividend growth over 5 years
113 %Continuous growth
–Payout Ratio 5 years average
23 %Dividend History 600276
Stock Valuation 600276
Financials 600276
Results | 2019 | Dynamics |